Switching to Retatrutide from Tirzepatide or Semaglutide

Retatrutide is not yet approved by the FDA and is not available by prescription. As of February 2026, there is no way to switch from semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) to retatrutide outside of a clinical trial. No switching protocols exist because the drug has not reached the market.

This article covers what we know about switching between GLP-1 class drugs generally, why people are interested in retatrutide specifically, and how to find clinical trials if you want to explore access before approval.

Why People Want to Switch

Interest in switching to retatrutide is driven by its clinical trial results, which show substantially larger weight loss than currently approved drugs:

Retatrutide's triple-agonist mechanism adds glucagon receptor activation to the GLP-1 and GIP agonism found in tirzepatide. The glucagon component increases energy expenditure and promotes fat breakdown, which may explain the larger weight loss observed in trials. For people who have plateaued on semaglutide or tirzepatide, the possibility of a more effective drug is understandably appealing.

For a full explanation of the three receptors, see What Is Retatrutide (GLP-3)?.

Current Status: Not Available Outside Clinical Trials

To be direct: you cannot switch to retatrutide right now. Here is the current timeline:

• Phase 3 TRIUMPH trials are underway, with results expected throughout 2026
• NDA filing (the formal FDA application) is expected in late 2026 or early 2027
• FDA approval, if granted, is most likely in 2027
• Prescription availability would follow shortly after approval

Anyone claiming to sell retatrutide outside a clinical trial is selling an unregulated, unverified product. For more on this, see Retatrutide Cost & How to Get It.

For the full regulatory timeline, see Retatrutide FDA Approval Timeline.

What We Know About Switching Between GLP-1 Drugs

While no retatrutide-specific switching data exists, there is established clinical experience with switching between existing GLP-1 receptor agonists. Here is what that experience tells us:

No washout period is typically needed

When switching between semaglutide and tirzepatide (or between other GLP-1 drugs), clinicians generally do not require a washout period — a gap between stopping one drug and starting another. The standard practice is to stop the current medication and start the new one at the next scheduled dosing time.

Dose titration usually restarts

When switching to a new GLP-1 drug, patients typically begin at the starting dose and titrate up, regardless of what dose they were on previously. This is because different drugs have different potencies, receptor profiles, and side effect patterns. Starting at a high dose of a new drug based on the previous drug's dose could cause unnecessary side effects.

GI side effects may recur

Even if a patient has adapted to GI side effects on their current medication, switching to a new drug — especially one with a different receptor profile — may trigger a new round of nausea, diarrhea, or other GI symptoms during the titration phase.

Each drug has a different receptor profile

This is particularly relevant for a hypothetical switch to retatrutide:

A patient switching from semaglutide to retatrutide would be adding two entirely new receptor activations (GIP and glucagon). A patient switching from tirzepatide would be adding one (glucagon). The glucagon component in particular could introduce new physiological effects — both therapeutic (increased energy expenditure, liver fat reduction) and in terms of side effects.

How to Access Retatrutide Through Clinical Trials

The only legitimate way to receive retatrutide today is through Eli Lilly's Phase 3 clinical trial program. Several trials may still be recruiting participants.

How to search for trials

1. ClinicalTrials.gov — Search for "retatrutide" on ClinicalTrials.gov to see all registered trials, their locations, and eligibility criteria.
2. Lilly Trial Finder — Visit LillyTrialGuide.com for Eli Lilly's own trial search tool.
3. Ask your doctor — Your physician can help determine if you meet eligibility criteria and refer you to a participating trial site.

What to expect

• Clinical trial participants receive the study drug at no cost
• You may be randomized to placebo — there is no guarantee you will receive retatrutide
• Participants are monitored with regular medical visits, blood work, and assessments
• Most trials require you to stop any current GLP-1 medication before enrolling (with a defined washout period specified in the trial protocol)

What Happens After Approval

Once retatrutide is approved — potentially in 2027 — switching protocols will be developed based on real-world clinical data and prescriber experience. At that point, the decision to switch will involve:

• Evaluating your response to current therapy — if you are achieving good results on semaglutide or tirzepatide, switching may not be necessary
• Discussing potential benefits — retatrutide's triple mechanism may offer advantages for specific patients, particularly those with plateau weight loss, fatty liver disease, or inadequate response to current drugs
• Insurance and cost considerations — a new brand-name drug will likely have different coverage than established medications, especially if generic or biosimilar versions of semaglutide become available
• Titration planning — you and your doctor will need to plan the transition, including when to stop the current drug and how to titrate the new one

Frequently Asked Questions

Sources

• Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
• Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.
• ClinicalTrials.gov: Retatrutide trials

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

Do not use this information to make decisions about your health without consulting a qualified healthcare provider. Do not stop or change your current medication based on the existence of an unapproved drug. If you are considering switching weight loss medications, talk to your doctor about currently approved options.

This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.